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ABSTRACT 
Objective: The drawback associated with conventional eye drops needs development of novel ophthalmic delivery system with improved 
bioavailability and patient compliances. The objective of present work was to develop and evaluate mucoadhesive in situ ocular gel of Pefloxacin 
mesylate based on the concept of ion activated in situ gelation for the prolonged precorneal residence time.  
Methods: Formulations were prepared using Sodium Alginate as gelling agent and Hydroxy ethyl cellulose as mucoadhesive agent. Gels were 
evaluated for gelling capacity, bio adhesion force, rheological property, ex vivo and in vitro release profile for selection of optimized formulation.  
Results: Developed formulations with satisfactory clarity, pH, drug content, gelling capacity, viscosity and bio adhesion were selected for ex vivo and 
in vitro release studies. An optimum formulation which could sustain the release for 12hours was finalized for further evaluations like; 
antimicrobial efficacy and irritation test. Formulations were found to be non irritant, effective against the test organisms and exhibited Zero order 
release pattern and pseudoplastic rheology.  
Conclusion: The developed system with sodium alginate and hydroxyl ethyl cellulose can be a feasible alternative to conventional eye drops. 
Keywords: Ocular drug delivery, Sodium alginate, Hydroxyethyl cellulose, Sustained delivery, Flouroquinolone antibiotic. 
 
INTRODUCTION  
Conventional ophthalmic eye drop often results in poor 
bioavailability and therapeutic response due to rapid pre-corneal 
loss caused by nasolacrimal drainage and high tear fluid turnover. 
Several new preparations like ointments, inserts and collagen 
shields have been developed for ophthalmic use, not only to prolong 
the contact time of the vehicle on the ocular surface, but also to slow 
down the drug elimination. Even though successful results were 
obtained with these preparations it involves some disadvantages, 
such as blurred vision or patient non-compliances [1, 2].  
An alternative approach that significantly increases the precorneal 
residence time and bioavailability of the drug can be achieved by 
using the novel delivery system based on the concept of in situ gel 
formation. In situ gel forming system can be described as liquids 
dosage form that can be delivered in a drop form, and they undergo 
a phase transition in the ocular cul-de-sac to form a viscoelastic gel. 
In contrast to pre formed gelled formulations the in situ gelling 
system has an advantage of reproducible and accurate 
administration of drug and creates little to no problem of vision [3].  
An in situ gelling system consists of polymers that exhibit sol-to-gel 
phase transition due to change in a specific physicochemical 
parameter; the pH [4] temperature [5] and electrolyte composition 
[6] in the lacrimal fluid of the eye. In situ gel forming solution has 
been studies extensively to enhance ocular bioavailability and 
prolonged duration of action. A natural hydrophilic polysaccharide 
SA (SA) the sodium salt of alginic acid, is used in preparation of in 
situ gelling system as it forms polymeric dispersion in buffer that 
exhibit low viscosity up to pH 5 and converted to gel in contact with 
lacrimal fluid [3-7]. Despite the fact that, in situ gelling polymers can 
be applied to the conjunctival sac where they undergo sol to gel and 
facilitate drug delivery continuously, its viscosity alone cannot 
significantly prolong the precorneal residence time. Consequently 
the need of mucoadhesive polymers was emphasized to enhance pre 
corneal residence of in situ gel for improved bioavailability of drug. 
Muco adhesive polymers are macromolecular hydrocolloids with 
numerous hydrophilic functional groups and they may be natural, 
synthetic, or semi-synthetic in nature [8, 9]. In present study 
Hydroxy ethylcellulose (HEC) was included as mucoadhesive 
polymer and SA was chosen as in situ gelling agent since it exhibits 
several favorable biological properties such as biodegradability and 
non-toxicity [10].  
Pefloxacin is a flouro quinolone bactericidal antibiotic, which 
inhibits bacterial DNA replication as other flouroquinolones. 
Compared to other antibiotics it has wider antibacterial spectrum, 
better bioavailability, better ocular penetration, and has least 
chances of developing resistance to antibiotic [11, 12].  
Hence the aim of this study was to examine the potential use of SA 
and HEC in designing a long acting mucoadhesive in situ ophthalmic 
delivery system of pefloxacin mesylate. 
MATERIALS AND METHODS 
Perfloxacin mesylate was obtained from Smruthi Pharma Pvt Ltd., 
Kolhapur [India]. SA and Hydrox ethyl cellulose were purchased 
from S. D. Fine chemicals Ltd., Mumbai [India].  
Instruments used were UV-Vis Spectrophotometer [Shimadzu UV-
1700 PC, Shimadzu corporation, Japan], Brookfield Viscometer [LV-
DVE] Brookfield Engineering Labouratories INC USA], Dissolution 
Tester [USP XXXIII dissolution Tester, Electrolab, Mumbai, India] 
Preparation of In situ gelling systems of Pefloxacin mesylate  
SA in combination with hydroxyl ethyl cellulose was dissolved in 
Acetate buffer pH 5.0 by continuous stirring at 40 °C. Required 
quantity of Pefloxacin mesylate was added to polymeric solution 
and stirred to get a final drug concentration of 0.3% w/v. 
Mannitol [5% w/v] and Benzalkonium chloride [0.01 % w/v] 
was added later which acts as isotonicity adjusting agent and 
preservative, respectively. The complete formulas of the 
formulations are given in the [table1]. The formulations were 
filled in sterile 20 ml glass vials, capped with rubber closures 
and sealed with aluminum caps. The formulations in their final 
pack were terminally sterilized by autoclaving at 121 °C and 15 
psi for 20 min. The sterilized formulations were stored in 
refrigerator [4 °C – 8 °C] until further use. 
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C1 C2 C3 C4 C5 C6 C7 C8 C9 
Drug 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
SA 1 1 1 1.5 1.5 1.5 2 2 2 
Hydroxy ethyl cellulose 1 2 3 1 2 3 1 2 3 
Mannitol 5 5 5 5 5 5 5 5 5 
Benzalkonium 
chloride 
0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
Acetate buffer q. s q. s q. s q. s q. s q. s q. s q. s q. s 
 
In vitro gelation studies 
Formulations were evaluated for gelling capacity by placing a drop 
of the formulation in a vial containing 2 ml of freshly prepared STF 
and equilibrated at 37 °C. The gel formed, gelation time and the time 
taken for the gel to dissolve was assessed visually. The composition 
of simulated tear fluid (STF) was sodium chloride 0.670 g, sodium 
bicarbonate 0.200 g, calcium chloride 0.008g and purified water q. s 
100 g [9]. 
Rheological studies 
In order to evaluate the rheological behavior, viscosity of the 
formulations before and after addition of simulated lacrimal fluid 
was evaluated using Brookfield viscometer [RVE Model]. Studies 
were carried out at room temperature. Sample was placed in a 
suitable beaker and the instrument continuously sheared the 
material at various angular velocities from 10 to 100 rpm. The 
hierarchy of angular velocity was reversed and the average viscosity 
was determined. 
Measurement of bio adhesion force 
In this method excised sheep corneal membrane was immediately 
fixed with the mucosal side outwards onto a glass vial using a rubber 
band. Vials with the corneal membrane were stored at 37 °C for 5 
min. Then, the next vial with a section of the membrane was 
connected to a balance in an inverted position while the first vial 
was placed on a height adjustable pan. The gel was placed onto the 
corneal membrane of the first vial. Then, the height of the second 
vial was adjusted so that the membrane surfaces of both the vials 
came in close contact. A ten minute contact time was chosen. Then, 
the weight was allowed to increase in the pan by adding weights 
until the vials get detached. The bioadhesive force was the minimum 
weight required to detach two vials. 
The bioadhesive force, expressed as detachment stress in 
dynes/cm2
Where m is the weight added to the balance in grams; g is the 
acceleration due to gravity taken as 980 cm/s2; and A is the area of 
tissue exposed. Measurements’ were repeated three times for each 
of the gel preparations [13]. 
, was determined from minimal weights needed to detach 
the tissues from the surface of each formulation, using following 
equation. 




In vitro release studies 
The in-vitro release studies of all the formulations were carried out 
through cellophane membrane. Overnight soaked cellophane 
membrane was tied to one end of the specially designed glass 
cylinder which is open at both sides. With the help of metallic shaft 
the cylinder is suspended such that the membrane just touches the 
100 ml of STF medium in the flask of a USP rotating paddle 
apparatus. For release studies, the temperature of the medium was 
maintained at 37.2 °C and 10 ml of formulation was kept in the well 
of the diffusion cell. The paddle was lowered into the flask and 
rotated at 50 rpm. Aliquots of the medium were withdrawn 
everyone hour up to 12 h and each time equal volume of STF was 
replaced to the receptor medium. The absorbances were read by UV 
spectrophotometer at 272 nm and cumulative percentage drug 
releases were calculated [14]. 
Ex vivo corneal permeation studies using goat’s cornea 
Whole eye balls of goat were procured from a local slaughter house 
and corneas were used to study the trans corneal permeability. A 
diffusion cell was fabricated to evaluate drug permeation through a 
sheep's corneal membrane. The modified diffusion cell consists of an 
upper and lower chamber and it was separated by goat cornea. 
Simulated tear fluid was used as a diffusion medium. The 
formulation to be tested was added to the donor chamber with the 
help of a micropipette. The donor surface of the membrane was 
constantly in contact with simulated tear fluid. A temperature of 
37±0.5 °C was maintained throughout the study. A magnetic stirrer 
in the cell provided continuous agitation. At regular time intervals, 1 
ml of sample was withdrawn and replaced with fresh STF in order to 
maintain sink conditions. The samples were appropriately diluted 
and the absorbance was measured at 272 nm using a Shimadzu 
1700UV-VIS spectrophotometer [15]. 
Isotonicity evaluation 
Isotonicity is an important characteristic of the ophthalmic 
preparations. Isotonicity has to be maintained to prevent tissue 
damage or irritation of eye. Formulations were mixed with few 
drops of blood and observed under the microscope at 45 X 
magnification and compared with the standard solution containing 
pefloxacin. The shape of blood cell was compared with the standard 
solution containing pefloxacin [16]. 
Hemolysis test 
In vitro eye irritancy screening method described by Dharmendra 
Jain et al. was performed to predict the eye irritation potential of 
formulations. According to procedure 5 ml of whole blood was 
collected from healthy individual and EDTA was used as an 
anticoagulant. Blood was centrifuged at 1500 × g for 20 min. The 
buffy coat was removed and the packed cells [RBCs] were washed 
thrice with normal saline. Normal saline was added to the cells to get 
40–50% hematocrit. Positive and negative controls were prepared 
in two different test tubes by diluting 100 μl of RBC to 3 ml with 
double distilled water in positive control and normal saline in the 
negative control. In positive control RBC will be lysed and in 
negative control there will be absence of lyses. Formulations were 
incubated at 37 °C for1 hours with 100 μl RBCs in test tubes and 
volume was made up to 3 ml with normal saline. All the formulations 
were tested for haemolysis in triplicates. The blood samples were 
then centrifuged at 795 × g for 20 minutes and the absorbance of the 
supernatant was measured at 540 nm by UV spectrometer [17, 18]. 
Percentage hemolysis was calculated using the following formula:  
% Hemolysis =
Aborbance of sample
Absorance of 100% haemolysis
x 100 
Antimicrobial studies 
To ascertain the biological activity of the optimized formulation, the 
antimicrobial activity was carried out against Pseudomonas 
aeruginosa [MTCC 1934] and Staphylococcus aureus [MTCC 737]. A 
layer of nutrient agar [20 ml] seeded with test microorganism [0.2 
ml] was allowed to solidify in the petriplate. Cups were made on the 
solidified agar layer with the help of sterile borer with 4 mm 
diameter. The volume of the formulations [optimized formulation 
and standard drug solution] containing equal amount of the drug is 
poured into the cups. After keeping the Petri plates at room 
temperature for 4 h, the plates were incubated at 37 °C for 24 h. The 
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zone of inhibition obtained was measured by an antibiotic zone 
reader [19]. 
RESULTS AND DISCUSSION 
Preparation of formulations 
The use of SA in in situ gel-forming systems is substantiated by the 
property of SA showing low viscosity up to pH 5 and which 
coacervate in contact with tear fluid pH 7.4 [20]. However, from 
preliminary studies it was confirmed that SA concentrations 1 to 2% 
w/v does not exhibit the desired bioadhesive force and hence 
polymer HEC in the concentration range of 1 to 3 % w/v was added 
as bioadhesive polymer. The dose of the drug in the in situ gel 
formulation was calculated with respect to the dose of drug in 
marketed eye drops i. e 0.3 % w/v.  
Evaluation of formulations 
Interaction studies were carried out by FTIR spectra to check 
possible interaction among the ingredients in the formulations. No 
new bands were detected in spectra of physical mixtures when 
compared with drug and individual polymers. This revealed that the 
ingredients are compatible with each other and no interaction took 
place between drug and polymer mixture. The drug content, clarity 
and pH of the formulations were found to be satisfactory [table 2].  
Rheological studies of in situ gels 
Viscosity is one of the prerequisites of an in situ gelling system. 
Formulation should have an optimum viscosity that will allow easy 
instillation into the eye as a liquid drops and must undergo a rapid 
sol-to-gel transition in contact with tear fluid [6]. Rheological study 
of formulations [fig. 1] indicated that in situ gels exhibited pseudo-
plastic rheology i.e., viscosity is high under low shear rate and low 
under high shear rate conditions. This property offered the 
advantage of low viscosity during blinking and stability of tear film 
during inter-blinking periods [8]. An increase in pH to 7.4 [STF] 
caused the formulations to transform to gels with high viscosity.  
Bioadhesion force 
Direct relation was observed between polymer concentrations and 
detachment stress. As the concentration of polymers HEC and SA 
increased the Bioadhesion force is increased, [table 2]. Increase in 
bioadhesive force of formulations may be due to presence of HEC, 
which has an abundance of hydroxyl and ether groups along their 
length, which are responsible for the mucoadhesive properties [21]. 
 
 
Fig. 1: Rheological profile of prepared in situ formulations 
 
It can also be substantiated due to the presence of SA a polymer with 
high glucuronic acid content which forms 3 dimensional ionotropic 
hydrogel matrices, generally by preferential interaction of G 
moieties resulting in formation of inhomogenous gels [22] and also 
due to the low surface tension [31.5 mN/m] of the alginate, which is 
lower than the critical surface tension of the mucin coated cornea 
[38 mN/m], resulting in good spreading and adhesion [23]. Thus, the 
increase in the bioadhesive force will lead to increased retention 
time and therefore increased bioavailability. 
From the in vitro gelation studies [table 2] it was found that, all the 
formulations showed instantaneous gelation when contacted by 
tissue fluid [STF] and remained for extended hours after gelation. 
However, the nature of gel formed depends on the concentration of 
SA and HEC. Formulations C1 and C2 showed immediate gelation but 
remained for few hours, which may be due to lesser concentration of 
SA. Formulations C6, C8 and C9 produced very stiff gel; this may be 
attributed to higher concentration of HEC and SA. The desired gel 
was produced by C3, C4, C5 and C7which remained for an extended 
period. These four formulations were selected for further evaluation.
  


















C1 99.37 5.23 Clear + 78.4 82 450 R 
C2 98.23 5.25 Clear ++ 117.6 274 1230 R 
C3 97.56 5.24 Clear +++ 196 1092 1950 S 
C4 98.52 5.20 Clear +++ 313.6 140 920 S 
C5 98.12 5.22 Clear +++ 392 486 940 S 
C6 95.76 5.25 Clear +++ 509.6 1286 2090 R 
C7 98.72 5.21 Clear +++ 470.4 208 1360 S 
C8 96.36 5.20 Clear +++ 588 566 1880 R 
C9 95.22 5.24 Clear +++ 862.4 1396 2700 R 
+Gels after few minutes, dissolves rapidly,++Gelation immediate, remains for few hours and+++Immediate gelation, remains for extended period 
 
In vitro release studies 
The drug release data obtained for formulations C3, C4, C5, C7 and 
Pure drug is depicted in fig. 2. The release profile of a drug predicts 
how a delivery system might function and gives valuable insight into 
its in vivo behavior. The in vitro release studies of in situ gelling 
formulations of Pefloxacin mesylate were carried out using STF of 
pH 7.4 as the dissolution medium and 93.9%, 91.62%, 86.8 %, and 
89.6% of the drug was released in 12 h from the formulation C3, C4, 
C5 and C7 respectively.  
Ex vivo corneal permeation studies 
Corneal permeation studies were performed using isolated goat’s 
cornea using STF [pH 7.4] at 34±0.5 °C. Compared to pure drug the 
formulations C3, C4, C5 and C7 have sustained the release up to 6, 8, 
10 and 8hr respectively [fig. 3]. Viscosity and release profiles of the 
four formulations were considered for selecting an optimum 
formulation for further evaluation. Normally viscosity values in the 
range of 5-1000 cps significantly improve the contact time in the eye 
which is fruitful for ophthalmic use due to the fact that the ocular 
shear rate is very high particularly 0.03 s-1 during inter blinking 
periods to 4250–28,500s-1during the blinking period [24, 25]. At 
higher shear rate the formulations C4 and C5 exhibited viscosity 
[after gelation] 920cps and 940cps respectively [table 2], which was 
within the reported range. Simultaneously from in vitro and ex vivo 
studies it was found that formulation C5 showed better sustained 
release compared to C4 formulation. Hence the formulation C5 was 
selected as an optimized formulation 
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.  
Fig. 2: Comparison of In vitro release profile of selected formulations (C3, C4, C5 and C7) with Pure drug, The error bars indicates 
standard deviations of three tests. 
 
With the aim of increasing the cumulative drug release, Tween 20 a 
permeation enhancer was added to formulation in a concentration 
of 2% w/v and it was coded as C5a. Formulation C5a showed release 
of 94.01% [fig. 4] in comparison with that of formulation C5 with 
86.88% after 12 h. Thus Tween 20 in the C5 formulation has 
increased the release profile of the C5a formulation. Both the 
formulations C5 and C5a showed an initial burst release in 1 to 2 h. 
The initial burst release of the drug can be explained by the fact that, 
the in situ gelling system is formulated in water and hence the 
polymer was completely hydrated. When they come in contact with 
STF, the alginate forms 3-dimensional ionotropic hydrogel matrices, 
by the interaction of calcium ions with glucouronic acid residues of 
alginates resulting in the formation of inhomogeneous gel which can 
entrap the drug and sustain their release [3].  
The in vitro release data’s of formulations C5 and C5a were 
subjected to various kinetic models and the regression coefficient [r] 
values were found to be 0.9794 and 0.9841 respectively for Zero 
order plot [table 3]. Hence the best fit model for the optimized 
formulations was found to be zero order kinetic models. 
The in vitro drug release conditions may be very different from those 
likely to be encountered in the eye. However, the results clearly show 
that the gels have the ability to retain drug for the prolonged period of 
time [12 h] and premature drug release will not occur. 
  
 
Fig. 3: Comparison of Ex vivo release profile of selected formulations (C3, C4, C5 and C7) with Pure drug, The error bars indicates standard 
deviations of three tests 
 
 
Fig. 4: In vitro Drug release profile of optimized formulation C5 and C5a, 
 
The error bars indicates standard deviations of three tests 
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Table 3: Correlation coefficient values of various kinetic models for optimized formulations 
Formulation Regression Coefficient(r) 
Higuchi Matrix Peppas plot First order plot Zero order plot 
C5 0.8764 0.9711 0.8874 0.9794 
C5a 0.8817 0.9767 0.8329 0.9841 
 
Antimicrobial efficacy study 
Pefloxacin has been proved to exhibit superior antibacterial activity 
against Pseudomonas aeruginosa which is a causative organism of 
bacterial conjunctivitis. Hence in vitro antimicrobial activity was 
done, using strain of gram negative bacteria, pseudomonas 
aeruginosa [26]. Microbiological studies were carried out to 
ascertain the biological activity of the optimized formulation against 
microorganisms Staphylococcus aureus and Pseudomonas 
aeruginosa. Results of Antimicrobial studies are as shown in the 
table 4. The formulations C5 and C5a showed good antimicrobial 
efficacy which was comparable to that of pure drug. This study 
indicated that the Pefloxacin retained its antimicrobial efficacy even 
after formulated as an in situ gelling system. 
  
Table 4: Comparison of antimicrobial activity of pure drug and optimum formulations 




ZOI(mm) % Efficacy ZOI(mm) %Efficacy 
Standard (Pure Drug) 46 100 47 100 
C5 45 97.82 44 95.65 
C5a 41 89.13 44 95.65 
 
Hemolysis studies 
To check the hemo compatibility of the formulations hemolysis 
study was performed using red blood cells [RBCs]. Results of 
hemolysis study are shown in table 5. Ocular irritation generally 
results from cytotoxic reactions of the applied substances with 
ocular tissues. Hemolysis test is considered as a simple, rapid, and 
reproducible technique to assess ocular irritation based on damage 
to RBC membranes. Also, hemolysis assay offers good sensitivity and 
specificity and shows minimum difference with the Draize test 
among the different in vitro tests available [27]. Formulations C5 
and C5a showed negligible hemolysis of 3.6 and 3.8% respectively 
which was in the range of 0-4 %, similar to that of normal saline-
treated erythrocytes. 
 
Table 5: Results of Hemolysis studies of optimum formulations 
Formulations/control Absorbance at 540 nm Percentage hemolysis 
Positive control 0.442 100 % 
Negative control 000 0% 
C5 0.0161 3.642% 
C5a 0.0172 3.89% 
 
CONCLUSION 
An optimized ion activated in situ opthalmic gel of Pefloxacin 
mesylate can be formulated by using the combination of SA and HEC. 
Formulation was liquid at non physiological pH [pH 5] and 
underwent rapid gelation at physiological pH [pH 7.4]. The 
formulation was found to be clear, having good bioadhesion, and 
viscosity, and the release kinetic study showed sustained release for 
a period of 12hr that followed Zero order kinetics. Optimized 
formulation was isotonic, non irritant and exhibited good 
antimicrobial efficacy. Hence from all the above results we can 
conclude that prepared formulation can be conveniently administer 
in drop form that undergo a phase transition in the ocular cul-de-sac 
to form a viscoelastic gel, which increases pre corneal residence 
time and sustain the drug for the longer period of time.  
CONFLICT OF INTERESTS 
The authors report no conflicts of interest. The authors alone are 
responsible for the content and writing of the paper 
REFERENCES 
1. Gupta H, Velpandian T, Jain S. Ion and pH activated novel in-
situ gel system for sustained ocular drug delivery. J Drug 
Target 2010;18:499-505. 
2. Balasubramaniam J, Kant S, Pandit J. K.-In vitro and in vivo 
evaluation of the Gelrite gellan gum-based ocular delivery 
system for indomethacin. Acta Pharm 2003;53:251-61. 
3. Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming 
hydrogels for sustained ophthalmic drug delivery. 
J Controlled Release 2007;122:119-34. 
4. Manjappa AS, Nanjwade BK, Manvi FV, Murthy RSR. Sustained 
ophthalmic in situ gel of ketorolac tromethamine: rheology and 
in vivo studies. Drug Dev Res 2009;70:417-24.  
5. Shastri DH, Prajapati ST, Patel LD. Thermoreversible 
mucoadhesive ophthalmic in situ hydrogel: Design and 
optimization using a combination of polymers. Acta Pharm 
2010;60:349-60. 
6. Paulsson M, Hägerström H, Edsman K. Rheological studies of 
the gelation of deacetylated gellan gum [Gelrite] in 
physiological conditions. Eur J Pharm Sci 1999;9:99-105. 
7. Gonjari ID, Karmarkar AB, Khade TS, Hosmani AH, Navale RB. 
Use of factorial design in formulation and evaluation of 
ophthalmic gels of gatifloxacin: Comparison of different 
mucoadhesive polymers. Drug Discoveries Ther 2010;4:423-34. 
8. Hagerstrom H, Paulsson M, Edsman K. Evaluation of 
mucoadhesion for two polyelectrolyte gels in simulated 
physiological conditions using a rheological method. Eur J 
Pharm Sci 2000;9:301–9.  
9. Mohammed MM, Hoda AE, Magda W. Mucoadhesive liposomes 
as ocular delivery system: physical, microbiological, and in vivo 
assessment. Drug Dev Ind Pharm 2010;36:108-18.  
10. Séchoy O, Tissié G, Sébastian C, Maurin F, Driot JY, Trinquand C. 
A new long acting ophthalmic formulation of Carteolol 
containing alginic acid. Int J Pharm 2000;207:109-16.  
Preethi et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 8, 345-350 
350 
11. Gonzalez JP, Henwood JM. Pefloxacin: a review of its 
antibacterial activity, pharmacokinetic properties and 
therapeutic uses. Drugs 1989;37:628-68. 
12. Blondeau JM. Fluoroquinolones: mechanism of action, 
classification, and development of resistance. Surv Ophthalmol 
2004;49:73-8. 
13. Choi HG, Jung JH, Ryu JM, Yoon SJ, Oh YK, Kim CK. Development 
of in situ gelling and mucoadhesive acetaminophen liquid 
suppository. Int J Pharm 1998;165:33-44. 
14. Sultana Y, Aqil M, Ali A, Zafar S. Evaluation of 
carbopol-methylcellulose based sustained-release ocular 
delivery system for pefloxacin mesylate using rabbit eye model. 
Pharm Dev Technol 2006;11:313-9. 
15. Gonjari ID, Hosmani AH, Karmarkar AB, Godage AS, Kadam SB, 
Dhabale PN. Formulation and evaluation of in situ gelling 
thermoreversible mucoadhesive gel of Fluconazole. 
Drug Discoveries Ther 2009;3:6-9. 
16. Doijad RC, Manvi FV, Malleswara Rao VSN, Prajakta, Alsae. 
Sustained ophthalmic delivery of gatifloxacin from in situ 
gelling system. Indian J Pharm Sci 2006;68:814-8. 
17. Mitjans M, Infante MR, Vinardell MP. Human hemoglobin 
denaturation as an alternative to the Draize test for predicting 
eye irritancy of surfactants. Regul Toxicol Pharmacol 
2008;52:89-93. 
18. Dharmendra J, Edmund C, Ajit KB, Rinti B. Development of 
polyvinyl alcohol–gelatin membranes for antibiotic delivery in 
the eye drug delivery in the eye. Drug Dev Ind Pharm 
2011;37:167–77. 
19. Desi HA, Bhalla HL. Preparation and evaluation of new eye 
drops containing a combination of ciprofloxacin and 
dexamethasone. Indian Drugs 2000;37:112. 
20. Pandit J, Bharathi D, Srinatha A, Ridhurkar D, Singh S. Long 
acting ophthalmic formulation of indomethacin: evaluation of 
alginate gel systems. Indian J Pharm Sci 2007;69:37-40. 
21. Sechoy O, Tissié G, Sébastian C, Maurin F, Driot JY, Trinquand C. 
A new long acting ophthalmic formulation of Carteolol 
containing alginic acid. Int J Pharm 2000;207:109-16. 
22. Larsen B, Smidsrød O, Painter TJ, Haug A. Calculation of the 
nearest-neighbour frequencies in fragments of alginate from 
the yields of free monomers after partial hydrolysis; Acta Chem 
Scand 1970;24:726–8. 
23. Mohanambal E, Arun K, Abdul Hasan Sathali A. Formulation 
and Evaluation of pH-Triggered in situ Gelling System of 
Levofloxacin. Indian J Pharm Educ Res 2011;45:58-64. 
24. Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic 
delivery of ofloxacin from a PH triggered in situ gelling system. 
J Controlled Release 2001;73:205-11. 
25. Patel PB, shastri DH, shelat PK. Development and evaluation pH 
triggered in situ gelling ophthalmic gel formulations of 
ofloxacin. AJPTR 2011;1:430-45.  
26. Suman Y, Nayyar P. A comparative evaluation of 0.3% eye 
drops and in situ forming gel of pefloxacin mesylate in 
experimentally induced pseudomonas conjunctivitis. 
Continental J Pharmacol Toxicol Res 2008;2:1-5. 
27. Sharma P, Sharma JD. In vitro hemolysis of human erythrocytes 
by plant extracts with antiplasmodial activity. J 
Ethnopharmacol 2001;74:239–43. 
 
